Related Experiment Video

Updated: Mar 6, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Resveratrol as MDR reversion molecule in breast cancer: An overview

Nafiseh Sadat Alamolhodaei1, Aristidis M Tsatsakis2, Mohammad Ramezani3

  • 1Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association
|March 19, 2017
PubMed

Insights

Resveratrol may help overcome multidrug resistance in breast cancer. Combination therapies can improve resveratrol

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Breast cancer is a leading cause of cancer mortality in women globally.
  • Multidrug resistance (MDR) presents a significant challenge in breast cancer treatment.
  • Resveratrol, a phytoestrogen, has shown potential in cancer therapy, particularly for hormone-dependent cancers.

Purpose of the Study:

  • To review the literature on resveratrol's effects on multidrug resistance in cancer.
  • To specifically examine resveratrol's role in overcoming multidrug resistance in breast cancer.

Main Methods:

  • This review summarizes existing in vitro and in vivo studies.
  • Literature search focused on resveratrol, multidrug resistance, and breast cancer.

Main Results:

  • In vitro studies suggest resveratrol can reverse multidrug resistance.
  • Poor bioavailability of resveratrol limits its in vivo efficacy.
  • Combination therapy can enhance resveratrol's bioavailability and therapeutic effect.

Conclusions:

  • Resveratrol shows promise in combating multidrug resistance in breast cancer.
  • Overcoming bioavailability limitations through combination therapy is crucial for clinical application.
  • Further research into combination strategies is warranted to improve breast cancer treatment outcomes.
Keywords:
Breast cancerDaidzein (PubChem CID: 5281708)Daunorubicin (PubChem CID: 30323)Multidrug resistancePaclitaxel (PubChem CID: 36314)PhytoestrogensResveratrolTamoxifen (PubChem CID: 2733526)cis-resveratrol (PubChem CID: 1548910)doxorubicin (PubChem CID: 31703)trans-resveratrol (PubChem CID: 445154)

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K